Valuing a biotech startup is unlike valuing almost any other kind of company. There's often no revenue, sometimes no product candidate that has reached the clinic, and the central question investors are trying to answer isn't "how fast is this growing" but "what is the probability this asset ever reaches the market, and what is it worth if it does." Risk-adjusted net present value, or rNPV, is the standard framework the industry uses to answer that question, and understanding how it works is essential for any biotech founder preparing to raise capital.
What rNPV is and why it exists
Traditional discounted cash flow analysis assumes a company's projected cash flows will actually materialize. For a biotech asset, that assumption doesn't hold — most drug candidates fail somewhere in development, and the probability of failure varies enormously by phase, indication, and modality. rNPV solves this by multiplying the projected cash flows at each future stage by the probability that the asset actually reaches that stage, then discounting the result back to present value. The output is a valuation that reflects both the size of the opportunity and the realistic odds of getting there, rather than treating a Phase 1 asset as if its success were already assured.
This matters enormously for how founders and investors negotiate price. A simple, unadjusted discounted cash flow model applied to a preclinical asset would produce a valuation driven almost entirely by the size of the addressable market, with little regard for how far the science still has to travel. rNPV forces every party in the negotiation to make their assumptions about technical and regulatory risk explicit, which is part of why it has become the common language of biotech dealmaking — it's used not just by venture investors but by corporate business development teams pricing licensing deals and by investment bankers valuing public biotech companies with early pipelines.
The building blocks of an rNPV model
An rNPV model has four core components. First, a revenue forecast for the asset if approved, typically built from an epidemiology-based estimate of the treatable population, likely pricing, and expected market share versus competitors. Second, a cost forecast covering the remaining clinical trials, regulatory filings, and commercialization spend required to bring the asset to market. Third, probability-of-success assumptions at each stage of development — industry benchmark data from sources tracking historical approval rates by phase and therapeutic area is commonly used as a starting point, then adjusted for asset-specific factors like mechanism novelty and trial design. Fourth, a discount rate that reflects the risk and illiquidity of biotech investing, typically higher than discount rates used in other industries given the binary risk profile.
Each of these inputs deserves its own scrutiny during a raise. Revenue forecasts are often the most contested line in the model, since small changes in assumed pricing or market share can swing the output valuation by a wide margin — founders should be prepared to defend their epidemiology sourcing and pricing comparables in detail. Cost forecasts are frequently underbuilt by founders who haven't yet run a pivotal trial and don't appreciate how quickly site, patient recruitment, and regulatory costs compound at later phases. And because probability-of-success assumptions compound across every remaining stage of development, a model that looks only modestly optimistic at each individual phase can produce a wildly inflated overall valuation once those probabilities are multiplied together.
Where rNPV fits versus other valuation approaches
rNPV is particularly well suited to single-asset or early pipeline companies where cash flows are so distant and uncertain that comparable-company or market-multiple approaches are nearly meaningless. For companies with marketed products or late-stage, de-risked pipelines, comparable transaction and public-market multiples become more relevant alongside rNPV. For a broader look at how these approaches fit together and how investors triangulate a valuation across methods, see our overview of valuation models for biotechnology startups. Earlier-stage biotech companies can also benefit from understanding the venture capital method, which many investors use alongside rNPV to sanity-check ownership targets and expected returns.
In practice, most sophisticated biotech investors run more than one method in parallel and look for convergence, or a defensible explanation for divergence, rather than relying on any single number. A venture capital method calculation that implies a much higher ownership ask than an rNPV-derived valuation can suggest the return assumptions behind the VC method are too aggressive for the stage of risk the company is actually carrying, and reconciling the two is often a useful exercise for founders to walk through before a term sheet is on the table.
Common mistakes founders make with rNPV
The biggest mistake is overstating probability of success to inflate valuation — sophisticated biotech investors know the standard benchmark approval rates cold, and a model that deviates significantly from them without strong scientific justification will undermine credibility rather than support a higher price. Another common error is underestimating the capital and time required for the remaining development path, which both understates the cost side of the model and sets unrealistic expectations for how much the round being raised will actually fund. Founders should also be careful not to double-count risk by applying an overly aggressive discount rate on top of already risk-adjusted cash flows.
A related, more subtle mistake is treating the rNPV output as a single precise number rather than a range. Because the model compounds several uncertain inputs, small changes in any one assumption can move the final valuation substantially. Presenting a sensitivity analysis — showing how the valuation shifts under conservative, base, and optimistic assumptions for the variables that matter most — tends to land better with experienced biotech investors than presenting one number as if it were derived with precision the underlying science doesn't support.
Using rNPV in your fundraising narrative
Even if your lead investor builds their own rNPV model, presenting a credible one yourself signals scientific and financial rigor. Your pitch deck should include the key assumptions driving the valuation — target population size, pricing assumptions, and probability-of-success benchmarks — so investors can see exactly where to push back during due diligence. Being transparent about these assumptions, rather than presenting a single valuation number without its drivers, tends to build more investor trust over the course of a raise.
Founders should also be ready to walk investors through how the model changes at the next value inflection point. A model built for a Series A raise should make clear what a positive Phase 1 or Phase 2 readout would do to the probability-of-success assumptions and, in turn, to the valuation — this is often exactly the analysis investors are running themselves when deciding whether today's price offers enough potential upside relative to the risk being underwritten.
Structuring the round around development milestones
Because biotech value creation happens in discrete jumps tied to clinical and regulatory milestones, many biotech rounds are structured with milestone-based tranches or tied closely to a specific data readout. Understanding how liquidation preference stacks across financing rounds matters particularly in biotech, where companies often raise many rounds before any commercial revenue materializes. For data on standard financing terms used across the industry, Carta's venture data offers useful benchmarks on round structures and dilution.
Milestone-based structuring also affects how founders should think about dilution over the full life of the company. Because so much value is created at discrete data readouts rather than steadily over time, raising too much capital too early — before a value-inflecting milestone — can mean giving up more ownership than necessary, while raising too little can leave the company unable to reach the next readout that would justify a higher valuation. Building the rNPV model alongside a realistic financing plan, rather than treating valuation and fundraising strategy as separate exercises, helps founders calibrate round size to the actual capital needed to reach the next milestone.
If you're preparing an rNPV model and fundraising narrative for your biotech company, book a free consult with Quantum Growth Advisors — our team regularly helps life sciences founders structure Series A and later-stage rounds around credible, defensible valuation frameworks.